Testing effectiveness (Phase 2)UnknownNCT01830504What this trial is testingPhase II Pilot Open LabelWho this might be right forThyroid Cancers Hospices Civils de Lyon 47
Large-scale testing (Phase 3)Looking for participantsNCT06475989What this trial is testingStudy of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerWho this might be right forRefractory Differentiated Thyroid Gland Carcinoma ECOG-ACRIN Cancer Research Group 264
Testing effectiveness (Phase 2)UnknownNCT05182931What this trial is testingA Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)Who this might be right forThyroid Cancer Olivia Newton-John Cancer Research Institute 80
Testing effectiveness (Phase 2)Study completedNCT00094055What this trial is testingStudy of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid CancerWho this might be right forThyroid Neoplasms Pfizer 60
Testing effectiveness (Phase 2)Study completedNCT02614495What this trial is testingStudy of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid CarcinomaWho this might be right forThyroid Carcinoma Hutchison Medipharma Limited 66
Large-scale testing (Phase 3)Active Not RecruitingNCT04940052What this trial is testingStudy of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid CancerWho this might be right forDifferentiated Thyroid Cancer (DTC) Novartis Pharmaceuticals 153
Not applicableLooking for participantsNCT05733013What this trial is testingCollect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid CancerWho this might be right forThyroid CancerThyroidRefractory Thyroid Cancer Memorial Sloan Kettering Cancer Center 100
Testing effectiveness (Phase 2)Study completedNCT02702388What this trial is testingA Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety ProfileWho this might be right forThyroid Cancer Eisai Inc. 241
Early research (Phase 1)Ended earlyNCT02313012What this trial is testingSafety and PK Study of CC-90003 in Relapsed/Refractory Solid TumorsWho this might be right forNeoplasm Metastasis Celgene 19
Not applicableApproved For MarketingNCT03533361What this trial is testingExpanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in BrazilWho this might be right forThyroid Cancer Eisai Inc.
Testing effectiveness (Phase 2)Study completedNCT00098813What this trial is testingRomidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive IodineWho this might be right forRecurrent Thyroid CancerStage IV Follicular Thyroid CancerStage IV Papillary Thyroid Cancer National Cancer Institute (NCI) 20
Early research (Phase 1)Active Not RecruitingNCT04514484What this trial is testingTesting the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVWho this might be right forAdvanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more National Cancer Institute (NCI) 8
Large-scale testing (Phase 3)Ended earlyNCT03602495What this trial is testingDonafenib in Patients With Radioiodine-refractory Differentiated Thyroid CancerWho this might be right forDifferentiated Thyroid Cancer Suzhou Zelgen Biopharmaceuticals Co.,Ltd 204
Early research (Phase 1)Active Not RecruitingNCT05241834What this trial is testingLOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to TreatmentWho this might be right forCarcinoma, Non-Small-Cell LungThyroid Neoplasms Eli Lilly and Company 70
Not applicableUnknownNCT04858867What this trial is testingReinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)Who this might be right forDifferentiated Thyroid Cancer Leiden University Medical Center 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT03914300What this trial is testingTesting the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerWho this might be right forDifferentiated Thyroid Gland CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland Carcinoma+6 more National Cancer Institute (NCI) 11
Not applicableUnknownNCT06062563What this trial is testingStudy of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid CancerWho this might be right forLocally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Study completedNCT02973997What this trial is testingLenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)Who this might be right forColumnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular Carcinoma+23 more Academic and Community Cancer Research United 57
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284774What this trial is testingTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialWho this might be right forMalignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more National Cancer Institute (NCI) 5
Early research (Phase 1)Looking for participantsNCT04119024What this trial is testingGene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsWho this might be right forMetastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more Anusha Kalbasi 18